Effect of Conbercept Treatment on Macular Edema and Microvascular Structure in Eyes with Retinal Vein Occlusions

Abstract

Objective To evaluate the efficacy on best corrected visual acuity (BCVA) and microvascular structure changes of conbercept intravitreal injection for the treatment of macular edema (ME) secondary to different types of retinal vein occlusion (RVO) and to explore the baseline OCTA parameters which were related to the change of BCVA and CRT after the intravitreal conbercept injection to RVO. Methods A retrospective observational study was conducted involving 67 eyes from 67 patients who were diagnosed with ME secondary to RVO between April 2019 to December 2020. The subjects were divided into branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) according to the involved vessel, subsequently the subjects received intravitreal conbercept treatment. The BCVA and fundus microstructure were measured to identify predictors of effective outcomes. Results BCVA, central retinal thickness (CRT), fovea avascular zone (FAZ), and foveal vascular density (FVD) in superficial capillary plexus (SCP) were significantly changed from baseline to 6-month follow-up in both CRVO and BRVO. In the BRVO group, age and baseline BCVA were correlated with changes of BCVA, while the baseline CRT, FVD in the DCP, and parafovea vascular density (PFVD) in DCP were associated with changes of CRT ( P <0.05). In the CRVO group, the baseline BCVA was correlated with changes of BCVA, while age, gender, baseline CRT, FVD in DCP, and PFVD in DCP were associated with changes of CRT ( P <0.05). There were no serious adverse events (SAEs) related to the drug or the injection procedure. Conclusion Intravitreal injections of conbercept can improve BCVA and CRT and change the FVD in SCP effectively both in BRVO and CRVO groups. In addition, the baseline FVD and PFVD in the DCP were related to the change of CRT after intravitreal conbercept treatment.

Intelligent diagnosis of retinal vein occlusion based on color fundus photographs

“…RME is the main cause of severe visual impairment in patients with RVO [10] . Currently, the primary treatments for patients with RVO are vitreous injection, laser photocoagulation, and vitrectomy [11][12][13] . Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs can significantly improve visual acuity loss caused by RME [14] , and laser photocoagulation is often performed in patients with intraocular neovascularization [15] .…”

Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis

“…ME due to RVO (RVO-ME) is sight-threatening and unlikely to improve without treatment [4] , but can be treated by antivascular endothelial growth factor (anti-VEGF) drugs. Recent trials have shown that anti-VEGF therapies (ranibizumab, aflibercept and conbercept) can improve ME in RVO-ME patients [5][6][7] . Ranibizumab was the first and most extensively used anti-VEGF drugs [8] .…”